Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study

BACKGROUND: COVID-19 is associated with both venous and arterial thrombotic complications. While prophylactic anticoagulation is now widely recommended for hospitalized patients with COVID-19, the effectiveness and safety of thromboprophylaxis in outpatients with COVID-19 has not been established. S...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Am Heart J
Glavni autori: Capell, Warren H., Barnathan, Elliot S., Piazza, Gregory, Spyropoulos, Alex C., Hsia, Judith, Bull, Scott, Lipardi, Concetta, Sugarmann, Chiara, Suh, Eunyoung, Rao, Jaya Prakash, Hiatt, William R., Bonaca, Marc P.
Format: Artigo
Jezik:Inglês
Izdano: Elsevier Inc. 2021
Teme:
Trial Designs
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7871775/
https://ncbi.nlm.nih.gov/pubmed/33577800
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ahj.2021.02.001
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items